TheraRadar
Clinical-Stage Companies / POLYSAN Scientific & Technological Pharmaceutical Company

POLYSAN Scientific & Technological Pharmaceutical Company

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 5/1/2025

13
Total Trials
9
Phase 3
5
Phase 2
1
Recruiting
178
Score

Pipeline by Phase

Phase 3
9
Phase 2
5
Phase 1
1

Therapeutic Focus

Stroke Diabetic Ketoacidosis Influenza Acute Respiratory Infection Cholestasis, Intrahepatic

Clinical Trials (13)

NCT05935787 Phase 3 COMPLETED

Cytoflavin in the Complex Rehabilitation of Stroke Patients

Started: 6/30/2023

NCT06183229 Phase 3 COMPLETED

Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

Started: 9/15/2023

NCT04631484 Phase 3 COMPLETED

International Trial of Efficacy of Cytoflavin in Head Trauma

Started: 11/22/2020

NCT03849664 Phase 3 COMPLETED

Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery

Started: 6/2/2017

NCT04649203 Phase 3 COMPLETED

Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy

Started: 11/25/2020

NCT03418935 Phase 3 COMPLETED

Remaxol® in Mechanical Jaundice of Non-malignant Origin

Started: 4/3/2017

NCT03416062 Phase 3 COMPLETED

Remaxol® in Malignant Mechanical Jaundice

Started: 4/3/2017

NCT06955416 Phase 2 RECRUITING

REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis

Started: 5/1/2025

NCT06183242 Phase 2 COMPLETED

Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis

Started: 5/27/2023

NCT05147051 Phase 2 COMPLETED

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Started: 6/16/2021

NCT03861416 Phase 2 COMPLETED

"Unifuzol®" in Patients With Peripheral Arterial Disease

Started: 3/16/2018

NCT02930161 Phase 2 TERMINATED

Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

Started: 5/30/2016

NCT03028285 Phase 1 COMPLETED

Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers

Started: 7/15/2016

Drug Candidates

Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid) Placebo Reamberin Cycloferon Remaxa, enteric-coated tablets Remaxol Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid) Cytoflavin® solution Cytoflavin® enteric-coated tablet Placebo solution
Activity Status: Slowing
Last Trial Started: 5/1/2025
Last Trial Ended: 12/7/2024
Trials (12 months): 0
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.